ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.829T>C (p.Cys277Arg) (rs1064795369)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000480494 SCV000571115 likely pathogenic not provided 2018-08-24 criteria provided, single submitter clinical testing This variant is denoted TP53 c.829T>C at the cDNA level, p.Cys277Arg (C277R) at the protein level, and results in the change of a Cysteine to an Arginine (TGT>CGT). TP53 Cys277Arg was observed in at least one individual with a personal history of early-onset breast cancer and a family history of breast and prostate cancer (Desmond 2015). Although this variant was associated with reduced, but not null, binding to the consensus reporter sequence in one study and its interaction with the p21 protein varied across reports, multiple functional studies consistently associated TP53 Cys277Arg with decreased DNA binding specificity and reduced overall transactivation activity (Thukral 1995, Saller 1999, Kaesar 2002, Resnick 2003). Additionally, this variant is reported as having non-functional transactivation in the International Agency for Research on Cancer TP53 database based on functional assays by Kato et al. (2003). TP53 Cys277Arg was also shown to reduce TP53 apoptosis induction and to impact growth inhibition in yeast, but not in mammalian cells (Saller 1999, Inga 2001, Kotler 2018). TP53 Cys277Arg was not observed in large population cohorts (Lek 2016). This variant is located in the DNA binding domain (Bode 2004). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on the currently available evidence, we consider TP53 Cys277Arg to be a likely pathogenic variant.
Invitae RCV000819627 SCV000960298 uncertain significance Li-Fraumeni syndrome 2019-01-11 criteria provided, single submitter clinical testing This sequence change replaces cysteine with arginine at codon 277 of the TP53 protein (p.Cys277Arg). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and arginine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in an individual undergoing multigene panel testing for hereditary breast and ovarian cancer risk assessment (PMID: 26270727). ClinVar contains an entry for this variant (Variation ID: 421804). This variant has been reported to affect TP53 protein function, though the experimental data is conflicting in some cases (PMID: 7651437, 10449408, 11423991, 11756653, 12826609, 29979965). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.